Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease

被引：203

作者：

Rosenson, Robert S. ^{[1
]}

Davidson, Michael H. ^{[2
]}

Hirsh, Benjamin J. ^{[3
]}

Kathiresan, Sekar ^{[4
]}

Gaudet, Daniel ^{[5
,6
]}

机构：

[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[2] Univ Chicago, Pritzker Sch Med, Div Cardiol, Chicago, IL 60637 USA

[3] Mt Sinai Hosp, New York, NY 10029 USA

[4] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA

[5] Univ Montreal, Dept Med, ECOGENE 21, Chicoutimi, PQ, Canada

[6] Univ Montreal, Dept Med, Lipid Clin, Chicoutimi, PQ, Canada

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2014年 / 64卷 / 23期

关键词：

atherosclerosis; cardiovascular disease; genetics; triglyceride; triglyceride-rich lipoproteins; LOW-DENSITY-LIPOPROTEIN; CORONARY-HEART-DISEASE; APOLIPOPROTEIN C-III; ALIPOGENE TIPARVOVEC AAV1-LPLS447X; TISSUE-SPECIFIC EXPRESSION; CYTOSOLIC LIPID DROPLETS; GENOME-WIDE ASSOCIATION; EXTENDED-RELEASE NIACIN; NONFASTING TRIGLYCERIDES; SEVERE HYPERTRIGLYCERIDEMIA;

D O I：

10.1016/j.jacc.2014.09.042

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Triglycerides represent 1 component of a heterogeneous pool of triglyceride-rich lipoproteins (TGRLs). The reliance on triglycerides or TGRLs as cardiovascular disease (CVD) risk biomarkers prompted investigations into therapies that lower plasma triglycerides as a means to reduce CVD events. Genetic studies identified TGRL components and pathways involved in their synthesis and metabolism. We advocate that only a subset of genetic mechanisms regulating TGRLs contribute to the risk of CVD events. This " omic" approach recently resulted in new targets for reducing CVD events. (C) 2014 by the American College of Cardiology Foundation.

引用

页码：2525 / 2540

页数：16

共 50 条

[1] Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease Risk
Duell, P. Barton
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (02) : 153 - 155
[2] Genetics of Triglyceride-Rich Lipoproteins Guide Identification of Pharmacotherapy for Cardiovascular Risk Reduction
Shaik, Aleesha
Rosenson, Robert S.
CARDIOVASCULAR DRUGS AND THERAPY, 2021, 35 (03) : 677 - 690
[3] Triglyceride-Rich Lipoproteins, Remnants, and Atherosclerotic Cardiovascular Disease Risk
Bharadiya, Vishwesh M.
Rawal, Swasti
Jain, Vardhmaan
Chevli, Parag A.
Mehta, Anurag
CURRENT CARDIOVASCULAR RISK REPORTS, 2022, 16 (11) : 131 - 144
[4] Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease New Insights From Epidemiology, Genetics, and Biology
Nordestgaard, Borge G.
CIRCULATION RESEARCH, 2016, 118 (04) : 547 - 563
[5] Triglyceride-Rich Lipoproteins, Remnants, and Atherosclerotic Cardiovascular Disease Risk
Vishwesh M. Bharadiya
Swasti Rawal
Vardhmaan Jain
Parag A. Chevli
Anurag Mehta
Current Cardiovascular Risk Reports, 2022, 16 : 131 - 144
[6] Triglyceride-rich lipoproteins and cardiovascular diseases
Xu, Dandan
Xie, Lin
Cheng, Cheng
Xue, Fei
Sun, Chaonan
FRONTIERS IN ENDOCRINOLOGY, 2024, 15
[7] Triglyceride-Rich Lipoproteins
Kockx, Maaike
Kritharides, Leonard
CARDIOLOGY CLINICS, 2018, 36 (02) : 265 - +
[8] Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease
Ganda, Om P.
CURRENT OPINION IN LIPIDOLOGY, 2023, 34 (03) : 105 - 113
[9] Genetics of Triglyceride-Rich Lipoproteins Guide Identification of Pharmacotherapy for Cardiovascular Risk Reduction
Aleesha Shaik
Robert S. Rosenson
Cardiovascular Drugs and Therapy, 2021, 35 : 677 - 690
[10] Triglyceride-Rich Lipoproteins and Their Remnants as Silent Promoters of Atherosclerotic Cardiovascular Disease and Other Metabolic Disorders: A Review
Sascau, Radu
Clement, Alexandra
Radu, Rodica
Prisacariu, Cristina
Statescu, Cristian
NUTRIENTS, 2021, 13 (06)

← 1 2 3 4 5 →